• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中等剂量环磷酰胺和粒细胞集落刺激因子后外周血祖细胞最佳动员及后续植入的预测因素

Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF.

作者信息

Morton J, Morton A, Bird R, Hutchins C, Durrant S

机构信息

Bone Marrow Transplantation Unit, Royal Brisbane Hospital, Herston, Australia.

出版信息

Leuk Res. 1997 Jan;21(1):21-7. doi: 10.1016/s0145-2126(96)00059-8.

DOI:10.1016/s0145-2126(96)00059-8
PMID:9029182
Abstract

Fifty consecutive patients undergoing cyclophosphamide/G-CSF mobilization were studied for indicators predictive for adequate harvest (CD34+ cells > 2 x 10(6)/kg, CFU-GM > 1 x 10(5)/kg). Target yields following a single leukopheresis were achieved for 66% of patients (89% with no previous alkylation chemotherapy or radiotherapy). Previous alkylation therapy, radiotherapy and low collection day platelet count were predictive of poor collection yields. Following reinfusion, the median time to platelets > 20 x 10(9)/l (PLT > 20) was 10 days and to neutrophils > 500 x 10(6)/l (ANC > 500) was 13 days. Total CD34+ cells infused was predictive of early platelet engraftment. Previous radiotherapy was inversely predictive of neutrophil engraftment. For the majority of patients not exposed to alkylation therapy or radiotherapy, adequate progenitor cells can be collected following a single leukopheresis. In patients suitable for future autologous bone marrow transplantation it would seem appropriate to avoid or minimize radiotherapy and alkylation therapy exposure in the pre-collection period.

摘要

对50例接受环磷酰胺/粒细胞集落刺激因子动员的连续患者进行研究,以寻找预测采集充足(CD34+细胞>2×10⁶/kg,粒-巨噬细胞集落形成单位>1×10⁵/kg)的指标。66%的患者单次白细胞分离术后达到目标产量(既往未接受烷化剂化疗或放疗的患者为89%)。既往烷化剂治疗、放疗和采集日血小板计数低可预测采集产量不佳。回输后,血小板>20×10⁹/L(PLT>20)的中位时间为10天,中性粒细胞>500×10⁶/L(ANC>500)的中位时间为13天。输注的总CD34+细胞数可预测血小板早期植入。既往放疗与中性粒细胞植入呈负相关。对于大多数未接受烷化剂治疗或放疗的患者,单次白细胞分离术后可采集到足够的祖细胞。对于适合未来自体骨髓移植的患者,在采集前阶段似乎应避免或尽量减少放疗和烷化剂治疗暴露。

相似文献

1
Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF.中等剂量环磷酰胺和粒细胞集落刺激因子后外周血祖细胞最佳动员及后续植入的预测因素
Leuk Res. 1997 Jan;21(1):21-7. doi: 10.1016/s0145-2126(96)00059-8.
2
Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.环磷酰胺和粒细胞巨噬细胞集落刺激因子动员后采用单次大容量白细胞分离术进行外周血祖细胞采集的预测因素
J Clin Oncol. 1995 Mar;13(3):705-14. doi: 10.1200/JCO.1995.13.3.705.
3
Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma.低剂量环磷酰胺与粒细胞集落刺激因子联合应用后的祖细胞动员:101例预处理恶性淋巴瘤患者的祖细胞数量、质量及预测这些参数的因素分析
J Clin Oncol. 1997 Feb;15(2):535-46. doi: 10.1200/JCO.1997.15.2.535.
4
Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer.白细胞单采前细胞计数对生殖细胞癌患者高剂量化疗后采集结果的影响及祖细胞剂量与植入的相关性
J Clin Oncol. 1996 Apr;14(4):1114-21. doi: 10.1200/JCO.1996.14.4.1114.
5
Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.多发性骨髓瘤患者外周血中浆细胞和造血祖细胞的同时动员。
J Hematother. 1996 Aug;5(4):339-49. doi: 10.1089/scd.1.1996.5.339.
6
Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.采用化疗加重组人粒细胞集落刺激因子动员的血液干细胞进行清髓性预处理治疗后成功进行自体移植。
Exp Hematol. 1993 Apr;21(4):508-14.
7
Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.超越 CD34+ 细胞剂量:外周血造血干细胞动员方法(粒细胞集落刺激因子[G-CSF]、G-CSF 加plerixafor 或环磷酰胺 G-CSF/粒细胞-巨噬细胞[GM]-CSF)对集落形成单位-GM 数量、植入和第 100 天造血移植物功能的影响。
Transfusion. 2011 Sep;51(9):1995-2000. doi: 10.1111/j.1537-2995.2011.03085.x. Epub 2011 Mar 10.
8
Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery.单用非格司亭动员的自体造血干细胞移植治疗93例恶性肿瘤患者:回输的CD34+细胞数量是预测粒细胞和血小板恢复的唯一因素。
J Hematother. 1996 Dec;5(6):663-70. doi: 10.1089/scd.1.1996.5.663.
9
Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.祖细胞动员的随机交叉试验:大剂量环磷酰胺加粒细胞集落刺激因子(G-CSF)与粒细胞巨噬细胞集落刺激因子加G-CSF的比较
J Clin Oncol. 2000 May;18(9):1824-30. doi: 10.1200/JCO.2000.18.9.1824.
10
[Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].依托泊苷联合重组人粒细胞集落刺激因子与环磷酰胺联合重组人粒细胞集落刺激因子动员自体外周血干细胞的比较
Ai Zheng. 2003 Dec;22(12):1311-6.

引用本文的文献

1
Variant rs1801157 in the 3'UTR of SDF-1ß does not explain variability of healthy-donor G-CSF responsiveness.SDF-1β 3'非翻译区中的rs1801157变异不能解释健康供体对粒细胞集落刺激因子(G-CSF)反应性的变异性。
PLoS One. 2015 Mar 24;10(3):e0121859. doi: 10.1371/journal.pone.0121859. eCollection 2015.
2
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.不良造血干细胞动员剂:一项关于复发或难治性淋巴瘤患者发生率及危险因素的单机构研究
Am J Hematol. 2009 Jun;84(6):335-7. doi: 10.1002/ajh.21400.
3
ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients.
对于预处理的淋巴瘤患者,ESHAP方案联合粒细胞集落刺激因子(G-CSF)是一种比环磷酰胺1.5 g/m²联合G-CSF更优的造血干细胞动员方案:78例患者的配对分析
Br J Cancer. 2000 Jan;82(2):278-82. doi: 10.1054/bjoc.1999.0915.